Literature DB >> 20351549

Cardiac biomarkers - the old and the new: a review.

Vikas Singh1, Pedro Martinezclark, Mario Pascual, Eric Scot Shaw, William W O'Neill.   

Abstract

Biomarkers are biological parameters that can be objectively measured and quantified as indicators of normal biologic processes, pathogenic processes, or responses to a therapeutic intervention. Typically thought of as disease process screening, diagnosing, or monitoring tools, biomarkers may also be used to determine disease susceptibility and eligibility for specific therapies. Cardiac biomarkers are protein components of cell structures that are released into circulation when myocardial injury occurs. They play a pivotal role in the diagnosis, risk stratification, and treatment of patients with chest pain and suspected acute coronary syndrome and those with acute exacerbations of heart failure. Cardiac markers are central to the new definition of acute myocardial infarction put forward by the American College of Cardiology and the European Society of Cardiology. Active investigation has brought forward an increasingly large number of novel candidate markers but few have withstood the test of time and become integrated into contemporary clinical care because of their readily apparent diagnostic, prognostic, or therapeutic utility.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20351549     DOI: 10.1097/MCA.0b013e328338cd1f

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  10 in total

1.  Heart-type fatty acid-binding protein and its relation with morphological changes in rat myocardial damage model induced by isoproterenol.

Authors:  Sabaheta Hasić; Radivoj Jadrić; Esad Cosović; Emina Kiseljaković; Zakira Mornjaković; Mira Winterhalter-Jadrić
Journal:  Bosn J Basic Med Sci       Date:  2011-11       Impact factor: 3.363

Review 2.  Troponin in Cardiovascular Disease Prevention: Updates and Future Direction.

Authors:  Jason Hoff; William Wehner; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2016-03       Impact factor: 5.113

Review 3.  Vitamin D in Cardiovascular Disease.

Authors:  Alkippi Nitsa; Marina Toutouza; Nikolaos Machairas; Anargyros Mariolis; Anastassios Philippou; Michael Koutsilieris
Journal:  In Vivo       Date:  2018 Sep-Oct       Impact factor: 2.155

4.  Biomarkers in the management of heart failure.

Authors:  Han-Na Kim; James L Januzzi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2010-12

5.  Identifying Cardiac Diseases using Cardiac Biomarkers in Rhesus Macaques (Macaca mulatta).

Authors:  Yu Ueda; JoAnn L Yee; Amber Williams; Jeffrey A Roberts; Kari L Christe; Joshua A Stern
Journal:  Comp Med       Date:  2020-08-10       Impact factor: 0.982

6.  2-Deoxy-d-Glucose (2-DG)-Induced Cardiac Toxicity in Rat: NT-proBNP and BNP as Potential Early Cardiac Safety Biomarkers.

Authors:  P S Terse; P S Joshi; N R Bordelon; A M Brys; K M Patton; T P Arndt; T P Sutula
Journal:  Int J Toxicol       Date:  2016-02-02       Impact factor: 2.032

7.  Relationship between serum cardiac troponin T level and cardiopulmonary function in stable chronic obstructive pulmonary disease.

Authors:  Kumiko Hattori; Takeo Ishii; Takashi Motegi; Yuji Kusunoki; Akihiko Gemma; Kozui Kida
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-02-10

Review 8.  Cardiopulmonary and inflammatory biomarkers in heartworm disease.

Authors:  Elena Carretón; Rodrigo Morchón; José Alberto Montoya-Alonso
Journal:  Parasit Vectors       Date:  2017-11-09       Impact factor: 3.876

9.  Perspectives on the value of biomarkers in acute cardiac care and implications for strategic management.

Authors:  Antoine Kossaify; Annie Garcia; Sami Succar; Antoine Ibrahim; Nicolas Moussallem; Mikhael Kossaify; Gilles Grollier
Journal:  Biomark Insights       Date:  2013-09-03

10.  Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.

Authors:  Kawa Dizaye; Rojgar H Ali
Journal:  BMC Pharmacol Toxicol       Date:  2019-05-03       Impact factor: 2.483

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.